Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh filed a Schedule 13G with the SEC on November 16, 2026, reporting beneficial ownership of 1,410,000 shares of common stock in Faeth Therapeutics, Inc., a Delaware-incorporated therapeutics company headquartered in Austin, Texas.
Key Highlights
- Reporting persons: Avoro Capital Advisors LLC, a Delaware limited liability company, and Behzad Aghazadeh, identified as portfolio manager and controlling person of Avoro.
- Shares held: Each reporting person disclosed beneficial ownership of 1,410,000 shares of Faeth Therapeutics common stock, par value $0.0001 per share (CUSIP 81728A207).
- Ownership percentage: The 1,410,000 shares represent 5.46% of the class, calculated against 25,840,425 shares outstanding as of July 30, 2026.
- Voting and dispositive power: Both Avoro and Dr. Aghazadeh each reported sole voting power and sole dispositive power over all 1,410,000 shares, with no shared voting or dispositive power.
- Investment purpose: According to the filing, the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
- Triggering event date: The event requiring the filing occurred on September 30, 2026.
Avoro Capital Builds a Position in Faeth Therapeutics Through Its Life Sciences Fund
According to the filing, Avoro Capital Advisors LLC, which the document describes as providing "investment advisory and management services," acquired the reported shares on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company. The filing identifies Faeth Therapeutics, Inc. as a Delaware corporation with principal executive offices at 701 Tillery Street #12 #1010, Austin, Texas 78702. The company's common stock carries a par value of $0.0001 per share and is identified by CUSIP number 81728A207.
The 5.46% ownership figure was derived using a share count of 25,840,425 shares of common stock outstanding as of July 30, 2026, as reported in the company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 4, 2026, according to the Schedule 13G. The filing notes that Avoro Life Sciences Fund LLC "has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the shares of Class A Common Stock."
Dr. Aghazadeh is listed in the filing as a United States citizen and is classified as a holding company or control person (HC) and individual (IN), while Avoro Capital Advisors LLC is classified as an investment adviser (IA) and other (OO). The filing states that it "should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein." Both parties signed the filing on November 16, 2026, with Scott Epstein, identified as Chief Operating Officer and Chief Compliance Officer, signing on behalf of Avoro Capital Advisors LLC.
What Was Disclosed
Avoro Capital Advisors LLC and Behzad Aghazadeh filed a Schedule 13G disclosing combined beneficial ownership of 1,410,000 shares, or 5.46%, of Faeth Therapeutics, Inc. common stock, acquired for investment purposes through Avoro Life Sciences Fund LLC, with the triggering event dated September 30, 2026.




Please wait processing your request...